Table 1 Patients' characteristics by histological types.

From: Implications of unconventional histological subtypes on magnetic resonance imaging and oncological outcomes in patients who have undergone radical prostatectomy

 

Pathological type

Total (n = 293)

P value

With CH (n = 211 )

With UH (n = 82)

Median age (range), years

67 (46–77)

70 (46–77)

67 (46–77)

0.0027#

Median initial PSA (range), ng/mL

7.31 (2.3–87.16)

7.96 (0.603–75.27)

7.6 (0.603–87.16)

0.6621#

Biopsy positive core, % (range)

27 (6–100)

38 (6–100)

27 (6–100)

0.1181#

Biopsy GG, n (%)

 < 0.001*

 ≤ 3

170 (80.6)

44 (53.7)

214 (73)

 

 4

24 (11.4)

28 (34.1)

51 (17.4)

 

 5

17 (8.0)

10 (12.2)

28 (9.6)

 

Pathological types

–

 Acinar adenocarcinoma

211 (100)

0 (0)

  

 IDC-P

0 (0)

3 (3.7)

  

 Ductal

0 (0)

14 (17.1)

  

 Cribriform

0 (0)

67 (81.7)

  

 Mixed

0 (0)

5 (6.1)

  

cT stage, n (%)

0.2636*

 ≤ 2c

192(91.0)

71 (86.6)

263 (89.8)

 

 ≥ 3a

19 (9.0)

11 (13.4)

30 (10.2)

 

cN stage, n (%)

 0

211 (100)

82 (100)

  

 1

0

0

  

NCCN risk classification

 < 0.001*

 Low

32 (15.2)

2 (2.4)

34 (11.6)

 

 Intermediate

123 (58.3)

39 (47.6)

162 (55.3)

 

 High

56 (26.5)

41 (50)

97 (33.1)

 

EAU risk classification

 < 0.001*

 Low

32 (15.2)

2 (2.4)

34 (11.6)

 

 Intermediate

114 (54)

32 (39)

146 (49.8)

 

 High

65 (30.8)

48 (58.5)

113 (38.6)

 

Location of MRI, n (%)

0.0706*

 TZ

79 (37.4)

22 (26.8)

101 (34.5)

 

 PZ

132 (62.6)

59 (72.0)

191 (65.2)

 

PI-RADS v2.1 score, n (%)

0.0443*

 ≤ 3

63 (29.9)

14 (17.1)

77 (26.3)

 

 ≥ 4

148 (70.1)

67 (81.7)

215 (73.4)

 

pT stage, n (%)

0.0794*

 ≤ 2c

158 (74.9)

53 (64.6)

211 (72)

 

 ≥ 3a

53 (25.1)

29 (35.4)

82 (28)

 

Lymph node dissection

 < 0.001*

 Yes

67 (31.8)

81 (98.8)

148 (50.5)

 

 No

144 (68.2)

1 (1.22)

145 (49.5)

 

pN stage, n (%)

   

0.3234*

Positive

2 (0.9)

2 (2.4)

4(1.4)

 

Pathological GG, n (%)

0.0056*

 ≤ 3

169 (80.1)

53 (64.7)

222 (75.8)

 

 4

16 (7.6)

17 (20.7)

33 (11.2)

 

 5

26 (12.3)

12 (14.6)

38 (13)

 

Median tumor volume, (range), cm3

2.13 (0.03–25.96)

2.89 (0.18–37.63)

2.29 (0.03–37.63)

0.0002#

RM positive, n (%)

63 (29.9)

25 (30.5)

88 (30)

0.9159*

Disease progression, n (%)

32 (15.2)

24 (29.3)

57 (19.5)

0.0062*

  1. CH conventional histology, UH unconventional histology, PSA prostate-specific antigen, GG gleason grade group, IDC-P intra-ductal carcinoma of the prostate, NCCN National Comprehenesive Cancer Network, EAU European Association of Urology, PI-RADS prostate imaging reporting and data system, pT pathological T, pN pathological N, RM resection margin.
  2. #Student's t-test.
  3. *χ2 test.
Back to article page